Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Gening Jiang, Han Zhang et al.|Signal Transduction and Targeted Therapy|2024Cited by 30
Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancerJie Dai, Gening Jiang, Xinsheng Zhu et al.|Translational Lung Cancer Research|2022Cited by 19
Nanog maintains stemness of Lkb1‐deficient lung adenocarcinoma and prevents gastric differentiationXinyuan Tong, Hongbin Ji, Wei‐Qiang Gao et al.|EMBO Molecular Medicine|2021Cited by 17
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trialDongliang Bian, Peng Zhang, Shuyu Ji et al.|Nature Communications|2025Cited by 11